Page 17 - Michael Erman News Today

Structure Therapeutics diabetes pill missed market expectations for weight loss in a mid-stage trial and also fell short of results from a similar treatment from rival Eli Lilly, sending the biotech...

By Michael Erman (Reuters) -Structure Therapeutics' diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of re...

By Michael Erman (Reuters) -Structure Therapeutics diabetes pill missed market expectations for weight loss in a mid-stage trial and fell short of results ...

An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Merck's Keytruda cut the chance of recurrence or death from melanoma by half after three years, showing that benefits demonstrated a year ago have held up over time. The combination of the personalized cancer vaccine and Merck's blockbuster immunotherapy cut the risk of recurrence or death of the most deadly skin cancer by 49% compared with Keytruda alone in the midstage trial, the compan...

WASHINGTON -The makers of a respiratory syncytial virus immunization for infants that has been in tight supply will deliver an additional 230,000 doses in January, the White House said on Thursday,... -December 14, 2023 at 04:38 pm EST - MarketScreener

By Michael Erman and Patrick Wingrove (Reuters) -An experimental messenger RNA cancer vaccine developed by Moderna and Merck & Co paired with Mercks ...

(Reuters) -Pfizer said on Tuesday it expects to close its $43 billion deal to buy cancer drugmaker Seagen later this week and plans to create a new oncology division that includes the acquisition early next year. Pfizer also said Chief Commercial Officer Angela Hwang would step down, and that it will split the its commercial business, not including oncology, into two divisions, one focused on the United States and the other on the rest of the world. In October, Pfizer slashed its full-year rev...

It marks the second large deal for AbbVie in the past week, coming days after it agreed to buy cancer drug developer ImmunoGen for $10.1 billion in cash, highlighting its appetite to place big bets on promising new medicines. It is paying $45 per share in cash for Cerevel, which is developing drugs for Alzheimer's, Parkinson's, psychosis, epilepsy, and panic disorder. Its experimental drug emraclidine is in midstage trials as a treatment for schizophrenia that will yield data the com...

Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of its midstage trial with high rates of side effects such as nausea and vomiting.

(Reuters) -Pfizer said on Friday it would not advance a twice-daily version of oral weight-loss drug danuglipron into late-stage studies after most patients dropped out of an earlier trial with high rates of side effects such as nausea and vomiting. Although Pfizer has a once-daily version of the weight-loss pill in the works, the decision still marks a blow to its ambition of entering a booming market that analysts expect to be worth $100 billion by the end of the decade. Pfizer said the drug...